Lannett Advances Its Insulin Glargine
Rival To Sanofi’s Lantus Gets Positive Feedback From FDA
After receiving “positive feedback” from the US Food and Drug Administration on its biosimilar insulin glargine, Lannett plans to move forward with its development activity.
